STROKE - A POSSIBLE ADVERSE EFFECT OF COMBINATION THERAPY WITH PARITAPREVIR/RITONAVIR/OMBITASVIR + DASABUVIR. CASE REPORT
The development of direct-acting antiviral agents against hepatitis C virus has revolutionized the management and control of this important liver disease. Combination therapy with paritaprevir/ritonavir/ombitasvir + dasabuvir is considered one of the most effective and well-tolerated regimens used to treat chronic hepatitis C, with response rates over 95%. Ease of administration, excellent tolerance, and the absence of severe side effects have made treatment of chronic hepatitis C possible even in patients with severe fibrosis and in those with comorbidities. Insomnia, headache and fatigue are the most commonly reported side effects, the serious adverse events being uncommon. We will report a case of stroke as a possible serious adverse effect during treatment with paritaprevir/ritonavir/ombitasvir + dasabuvir (PrOD) in a 61-year-old male, former smoker, without cardiovascular history, in whom a conflict situation resulted in a hypertensive episode accompanied by paresthesia in the upper and lower right limbs, vertigo, equilibrium disorder, which turned out to be a stroke. Conclusions: Because the reported case may be a rare serious effect during the treatment with parita previr/ritonavir/ombitasvir + dasabuvir in a patient with hepatitis C virus (HCV) cirrhosis and without a cardiovascular history, careful neurological monitoring is recommended during this therapeutic regimen.
2. Majamudar A, Kitson MT, Roberts SK. Systematic review: Current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 2016; 43: 1276-1292.
3. Wheeler-Singer A, Osinusi A, Brainard DM. Risk of cardiovascular and cerebrovascular events in hepatitis C patients fallowing completion of direct-acting antiviral therapy: a retrospective cohort study. J Hepatol 2017; 66(1): 282-283.
4. Zaid AM, Maher MM. Cerebrovascular accident; a possible serious adverse event of combined sofos-buvir-daclatasvir therapy: a case report. J Hepatol Gastroenterol 2017; 2(2): 1-4.
5. Kaneko R, Nakazaki N, Omori R, Yano Y, Ogawa M, Sato Y. Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience. World J Hepatol 2018; 10: 88-94.
6. Smolders EJ, de Kanter CT, van Hoek B, et al. Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and or renal impairment. Drug Saf 2016; 39: 589-611.
7. Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews 2017; 6: CD012143.
8. Trifan A, Stanciu C, Gheorghe L, Iacob S, Curescu M, Cijevschi Prelipcean C, Stefanescu G, Girleanu I, Chiriac S, Mihai C, Brisc C, Goldis A, Sporea I, Miftode E, Bataga S, Rogoveanu I, Preda C, Caruntu FA, Singeap AM. Efficacy and safety of paritaprevir/ ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older. Medicine (Baltimore) 2017; 96(50): e9271.
9. Saxena V, Khungar V, Verna EC, Levitsky J, Brown Jr RS, Hassan MA, Sulkowski MS, O’Leary JG, Koraishy F, Galati JS, Kuo AA, Vainorius M, Akushevich L, Nelson DR, Fried MW, Terrault N, Reddy KR. Safety and Efficacy of Current Direct-Acting Antiviral Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Results From the HCV-TARGET Study. Hepatology 2017; 66(4): 1090-1101.
10. Liao CC, Su TC, Sung FC, Chou WH, Chen TL. Does Hepatitis C Virus Infection Increase Risk for Stroke? A Population-Based Cohort Study. PLoS ONE 2017; 7(2): e31527.
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
N.B. All the authors must sign this form